profit from every $100 of sales.
$0$100
Inhibikase Therapeutics
$1.63+5.16% today
-0.6% in 1 year
1-year low $1.411-year high $2.52
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Inhibikase Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$48.3 million of profit last year.
SalesProfit
Inhibikase Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Inhibikase Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Inhibikase Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -18 | -20 | -29 | -53 | |
| -18 | -20 | -29 | -53 | |
| -18 | -19 | -28 | -48 | |
| -4.28 | -3.16 | -1.16 | -0.49 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 25 | 15 | 99 | 181 |
| Cash | 7 | 9 | 56 | 139 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 4 | 4 | 4 | 8 |
| 21 | 11 | 95 | 173 | |
| 4 | 6 | 24 | 98 | |
| -67.0% | -141.5% | -23.8% | -24.4% | |
| -85.8% | -173.3% | -29.0% | -27.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -17 | -18 | -19 | -28 | |
| 0 | 0 | – | 0 | |
| -18 | -18 | -19 | -28 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 1 | 8 | 15 |
Valuation
- –
- –
- –
- 1.2×
- –
- –
- –
- -12.2%
- -21.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -26.6%
- -68.7%
- -46.9%
- -26.6%
- -26.6%
- –
Growth
- –
- –
- −45.1%
- –
- +138.6%
Financial health
- -2.7×
- 0.00
- 0.0%
- –
- 21.70
- 21.70
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 958
Bottom 21%of 888
Bottom 8%of 987
What analysts expect
- Average price target
- $4.00
- Range
- $4.00 – $4.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.10 | -0.10 | +0.0% |
| Mar 26, 2026 | -0.09 | -0.12 | +25.0% |
| Nov 14, 2025 | -0.13 | -0.13 | +0.0% |
| Aug 14, 2025 | -0.11 | -0.09 | −22.2% |
| May 14, 2025 | -0.15 | -0.11 | −36.4% |
| Mar 26, 2025 | -0.63 | -0.10 | −530.0% |
| Nov 14, 2024 | -0.65 | -0.38 | −71.1% |
| Aug 14, 2024 | -0.66 | -0.58 | −13.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
64Pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
23No pass
Questions about Inhibikase Therapeutics
Is Inhibikase Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Inhibikase Therapeutics AI analysis
What does Inhibikase Therapeutics do?
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. It is in Biotechnology.
Does Inhibikase Therapeutics pay a dividend?
No. Inhibikase Therapeutics does not pay a dividend at the moment.
Is Inhibikase Therapeutics stock halal?
No. Inhibikase Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 61% of its market value, at or above the 33% limit. How we check
How has Inhibikase Therapeutics stock done over the past year?
Down 0.6% over the past twelve months, to $1.63. It traded between $1.41 and $2.52 and is 35.3% below its high.
Who are Inhibikase Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Inhibikase Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.